What is Wugen?
Founded in 2018, Wugen Inc. is at the forefront of biotechnology, specializing in the development of a novel CAR-T therapy platform. Their innovative "off-the-shelf" fratricide-resistant CAR-T cell therapy is designed to address T-cell malignancies. Wugen leverages state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy to overcome challenges that have historically hindered the clinical advancement of allogeneic CAR-T cells. The company's foundation is built upon technology licensed from Washington University in St. Louis, positioning it as a key player in the next generation of cancer treatments.
How much funding has Wugen raised?
Wugen has raised a total of $224.5M across 2 funding rounds:
Private Equity
$115M
Private Equity
$109.5M
Private Equity (2025): $115M with participation from RiverVest Venture Partners, LYZZ Capital, Abingworth, Tybourne Capital Management, Lightchain Capital, Aisling Capital, Fidelity International Hong Kong, and ICG
Private Equity (2025): $109.5M, investors not publicly disclosed
Key Investors in Wugen
RiverVest Venture Partners
RiverVest Venture Partners is a venture capital firm dedicated to building life science companies that address significant unmet medical needs, focusing on scientific innovation and entrepreneurial support.
LYZZ Capital
LYZZ Capital is a global venture capital and private equity firm with a strong focus on healthcare investments, leveraging extensive expertise from the pharmaceutical and biotech industries to target assets and technologies addressing critical medical needs.
Abingworth
Abingworth is a transatlantic life sciences investment firm that partners with management teams to transform cutting-edge science into novel medicines, supporting companies from seed stage through clinical development.
What's next for Wugen?
With substantial enterprise-level backing and a recent strategic investment, Wugen is poised for accelerated growth and development. The significant capital infusion is expected to fuel the advancement of its novel CAR-T therapy platform, particularly its "off-the-shelf" allogeneic CAR-T cell therapy for T-cell malignancies. This strategic financing will likely support further research and development, clinical trials, and the scaling of its gene editing technologies. The company's focus on addressing unmet medical needs in oncology positions it for significant impact and potential market leadership in the competitive biotechnology sector.
See full Wugen company page
